These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 9796960

  • 1. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
    Goren MP, Houle JM, Bush DA, Li JT, Newman CE, Brade WP.
    Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP, Epelman S, Bush DA.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993
    [Abstract] [Full Text] [Related]

  • 4. Bioavailability of orally administered mesna.
    Burkert H, Lücker PW, Wetzelsberger N, Breuel HP.
    Arzneimittelforschung; 1984 Sep; 34(11):1597-600. PubMed ID: 6441581
    [Abstract] [Full Text] [Related]

  • 5. Reduction of dimesna to mesna by the isolated perfused rat liver.
    Goren MP, Hsu LC, Li JT.
    Cancer Res; 1998 Oct 01; 58(19):4358-62. PubMed ID: 9766664
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.
    el-Yazigi A, Ernst P, al-Rawithi S, Legayada E, Raines DA.
    J Clin Pharmacol; 1997 Jul 01; 37(7):618-24. PubMed ID: 9243355
    [Abstract] [Full Text] [Related]

  • 7. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 Jul 01; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
    Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT.
    J Clin Oncol; 1998 Feb 01; 16(2):616-21. PubMed ID: 9469350
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A crossover study after oral and intravenous administration of theophylline in male volunteers (absolute bioavailability of Afonilum tablets).
    Kaumeier HS, Kehrhahn OH, Neugebauer G, Schuppan D, Schwarz JA, Staib AH.
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul 01; 21(7):339-45. PubMed ID: 6885204
    [Abstract] [Full Text] [Related]

  • 12. Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.
    Kaumeier S, Kehrhahn OH, Morgenthaler H, Neugebauer G.
    Arzneimittelforschung; 1981 Jul 01; 31(9a):1653-7. PubMed ID: 7197980
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.
    Clin Cancer Res; 1997 Sep 01; 3(9):1507-18. PubMed ID: 9815837
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.